Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
USES OF EP4 RECEPTOR ANTAGONIST FOR TREATING IL-23 MEDIATED DISEASES
Document Type and Number:
Japanese Patent JP2017095511
Kind Code:
A
Abstract:
PROBLEM TO BE SOLVED: To provide compounds having selective EP4 receptor antagonism useful for treating immune diseases or allergies, or preventing or inhibiting the onset or progression of immune diseases or allergies.SOLUTION: The present invention discloses uses of 3-[2-(4-{2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl}phenyl)ethyl]-1-[(4-methylbenzene)sulfonyl]urea; and 4-[(1S)-1-({[5-chloro-2-(3-fluorophenoxy)pyridin-3-yl]carbonyl}amino)ethyl]benzoic acid or a pharmaceutically acceptable salt thereof for producing therapeutic or prophylactic medicines of IL-23 mediated diseases of at least one selected from inflammatory bowel disease (IBD), psoriasis, rheumatoid arthritis, and allergic contact dermatitis.SELECTED DRAWING: None

Inventors:
KANAZAWA KIYOSHI
NONOMURA KAZUHIKO
OKUMURA TAKAKO
KOIZUMI SHINICHI
Application Number:
JP2017013578A
Publication Date:
June 01, 2017
Filing Date:
January 27, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
RAQUALIA PHARMA INC
International Classes:
A61K31/437; A61K31/4418; A61K45/00; A61P1/04; A61P17/00; A61P17/06; A61P19/02; A61P29/00; A61P37/08
Attorney, Agent or Firm:
Ryu Iwatani